Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

FDA takes aim at opioid epidemic

Agency wants to pull opioid from market because it says the drug’s benefits don’t outweigh its risks

by Lauren K. Wolf
June 14, 2017 | A version of this story appeared in Volume 95, Issue 25

The U.S. Food & Drug Administration has requested that Endo Pharmaceuticals remove its painkiller Opana ER from the market. Opana ER’s active ingredient, oxymorphone, is an opioid similar to morphine but with an added hydroxyl group that makes it 10 times as potent. The agency says this is the first time it has taken steps to halt sales of an opioid over concerns of public abuse. In 2012, Endo reformulated Opana ER to make it harder for people to crush the drug, and thereby snort it, and to dissolve the drug, and thereby inject it. The firm did so with help from German drugmaker Grünenthal’s Intac technology, which uses a high-molecular-weight polyethylene oxide and proprietary excipients to make it difficult to break the pills into fine particles and to make them gel when dissolved. Still, people with opioid addiction have figured out ways to inject it, and FDA says illicit use of Opana ER has been associated with an outbreak of HIV and hepatitis C. “We are facing an opioid epidemic—a public health crisis, and we must take all necessary steps to reduce the scope of opioid misuse and abuse,” said newly appointed FDA commissioner Scott Gottlieb in a statement. “We will continue to take regulatory steps when we see situations where an opioid product’s risks outweigh its benefits.” Endo says it’s currently evaluating its “full range” of options.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.